La gestione degli anticoagulanti e delle complicanze emorragiche nei pazienti oncologici

Abstract

The presence of a malignancy is an important factor conditioning the choice, outcomes, and complications of anticoagulants in pathologic conditions where such agents are indicated. In addition, there is a relative paucity of data in this setting, because active cancer has been an important exclusion criterion in the main phase III randomized controlled trials comparing various anticoagulants. Only recently data have become available comparing the direct oral anticoagulants with low-molecular-weight heparins or warfarin for acute venous thromboembolism and atrial fibrillation, respectively, in patients with malignancies. Here, we briefly review the main points from data available in the literature in this setting, ongoing developments, and the main management strategies of hemorrhagic complications with the various drugs now available or forthcoming.